Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro
We investigated the incidence of AMS amongst a general population of trekkers on Mount Kilimanjaro, using the Lake Louise consensus scoring system (LLS). Additionally we examined the effect of prophylactic acetazolamide and different ascent profiles. Climbers on 3 different ascent itineraries were recruited. At 2743 m we recruited 177 participants (mean age 31, range [18-71]) who completed LLS together with an epidemiological questionnaire. At 4730 m participants (n=189, male=108, female=68, mean age 33, range [1871]) completed LLS, 136 of whom had been followed up from 2730 m. At 2743 m, 3% (5/177) of climbers were AMS positive, and 47% (89/189) of climbers from all itineraries were AMS positive at 4730 m. Of climbers attempting the Marangu itineraries, 33% (45/136) were taking acetazolamide. This group had a similar rate of AMS and no statistical difference in severity of LLS when compared with those not taking prophylactic drugs. We also did not demonstrate a difference between the incidence of AMS in climbers who did or did not take a rest day at 3700 m. However, there was a significant reduction in the incidence of AMS amongst pre-acclimatized subjects. Consistent with previous work, we found that the rate of AMS on Mount Kilimanjaro is high. Furthermore, at these fast ascent rates, there was no evidence of a protective effect of acetazolamide or a single rest day. There is a need to increase public awareness of the risks of altitude sickness and we advocate a pragmatic "golden rules" approach (http://www.altitude.org/altitude_sickness.php).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
High altitude medicine & biology - 11(2010), 3 vom: 01., Seite 217-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jackson, Stewart J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.01.2011 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1089/ham.2010.1003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM202132668 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM202132668 | ||
| 003 | DE-627 | ||
| 005 | 20231223223725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/ham.2010.1003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0674.xml |
| 035 | |a (DE-627)NLM202132668 | ||
| 035 | |a (NLM)20919888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jackson, Stewart J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2011 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We investigated the incidence of AMS amongst a general population of trekkers on Mount Kilimanjaro, using the Lake Louise consensus scoring system (LLS). Additionally we examined the effect of prophylactic acetazolamide and different ascent profiles. Climbers on 3 different ascent itineraries were recruited. At 2743 m we recruited 177 participants (mean age 31, range [18-71]) who completed LLS together with an epidemiological questionnaire. At 4730 m participants (n=189, male=108, female=68, mean age 33, range [1871]) completed LLS, 136 of whom had been followed up from 2730 m. At 2743 m, 3% (5/177) of climbers were AMS positive, and 47% (89/189) of climbers from all itineraries were AMS positive at 4730 m. Of climbers attempting the Marangu itineraries, 33% (45/136) were taking acetazolamide. This group had a similar rate of AMS and no statistical difference in severity of LLS when compared with those not taking prophylactic drugs. We also did not demonstrate a difference between the incidence of AMS in climbers who did or did not take a rest day at 3700 m. However, there was a significant reduction in the incidence of AMS amongst pre-acclimatized subjects. Consistent with previous work, we found that the rate of AMS on Mount Kilimanjaro is high. Furthermore, at these fast ascent rates, there was no evidence of a protective effect of acetazolamide or a single rest day. There is a need to increase public awareness of the risks of altitude sickness and we advocate a pragmatic "golden rules" approach (http://www.altitude.org/altitude_sickness.php) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Varley, James |e verfasserin |4 aut | |
| 700 | 1 | |a Sellers, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Josephs, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Codrington, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Duke, Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Njelekela, Marina A |e verfasserin |4 aut | |
| 700 | 1 | |a Drummond, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Sutherland, Andrew I |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, A A Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Baillie, J Kenneth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t High altitude medicine & biology |d 2000 |g 11(2010), 3 vom: 01., Seite 217-22 |w (DE-627)NLM111633427 |x 1557-8682 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2010 |g number:3 |g day:01 |g pages:217-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/ham.2010.1003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2010 |e 3 |b 01 |h 217-22 | ||